Evidence map›Paper›PMID 31418764›Full record

ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2019

Advances in targeted alpha therapy for prostate cancer.

G De Vincentis, W Gerritsen, J E Gschwend, M Hacker, V Lewington, J M O'Sullivan, M Oya, M Pacilio, C Parker, N Shore and 2 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Evolving role ofProstate cancer and prostatic diseases · 2021
    Pooled it
  2. DoesEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Recent Advances in Anti-Cancer Drugs.International journal of molecular sciences · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  13. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  14. Article
  15. Advances in aptamer-based nuclear imaging.European journal of nuclear medicine and molecular imaging · 2022
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Ac-EAZY! Towards GMP-Compliant Module Syntheses ofPharmaceuticals (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 7 countries.

G De VincentisDepartment of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza, University of Rome, Rome, Italy.
W GerritsenDepartment of Medical Oncology, Radboud UMC, Nijmegen, The Netherlands.
J E GschwendDepartment of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, Germany.
M HackerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
V LewingtonDepartment of Imaging Sciences and Biomedical Engineering, King's College, London, UK.
J M O'SullivanCenter for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland Cancer Center, Belfast City Hospital, Belfast, Northern Ireland.
M OyaDepartment of Urology, Keio University School of Medicine, Tokyo, Japan.
M PacilioMedical Physics Department, "Policlinico Umberto I" University Hospital, Rome, Italy.
C ParkerThe Royal Marsden Hospital, Sutton, UK.
N ShoreCarolina Urologic Research Center, Myrtle Beach.
O SartorTulane Cancer Center, Tulane University, New Orleans, USA. Electronic address: osartor@tulane.edu.
Targeted Alpha Therapy Prostate Working Group
Carolina Urologic Research Center · USKeio University · JPKing's College London · GBKlinikum rechts der Isar · DEMedical University of Vienna · ATPoliclinico Umberto I · ITRadboud University Nijmegen · NLRoyal Marsden Hospital · GBSapienza University of Rome · ITTulane University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity. In this review, we discuss the history, progress, and future potential of TαT in the treatment of prostate cancer, including dosimetry-individualized treatment planning, combinations with small-molecule therapies, and conjugation to molecules directed against antigens expressed by prostate cancer cells, such as prostate-specific membrane antigen (PSMA) or components of the tumor microenvironment. A clinical proof of concept that TαT is efficacious in treating bone-metastatic castration-resistant prostate cancer has been demonstrated by radium-223 via improved overall survival and long-term safety/tolerability in the phase III ALSYMPCA trial. Dosimetry calculation and pharmacokinetic measurements of TαT provide the potential for optimization and individualized treatment planning for a precision medicine-based cancer management paradigm. The ability to combine TαTs with other agents, including chemotherapy, androgen receptor-targeting agents, DNA repair inhibitors, and immuno-oncology agents, is under investigation. Currently, TαTs that specifically target prostate cancer cells expressing PSMA represents a promising therapeutic approach. Both PSMA-targeted actinium-225 and thorium-227 conjugates are under investigation. The described clinical benefit, safety and tolerability of radium-223 and the recent progress in TαT trial development suggest that TαT occupies an important new role in prostate cancer treatment. Ongoing studies with newer dosimetry methods, PSMA targeting, and novel approaches to combination therapies should expand the utility of TαT in prostate cancer treatment.

Indexed as

ActiniumAlpha ParticlesClinical Trials, Phase III as TopicDipeptidesHeterocyclic Compounds, 1-RingHumansMalePrecision MedicineProgression-Free SurvivalProstate-Specific AntigenProstatic NeoplasmsRadioimmunotherapyRadiopharmaceuticalsRadiotherapy Planning, Computer-AssistedTumor Microenvironment(225)Ac-PSMA-617ActiniumDipeptidesHeterocyclic Compounds, 1-RingProstate-Specific AntigenRadiopharmaceuticalsprostate cancerprostate-specific membrane antigen (PSMA)radium-223targeted alpha therapy (TαT)

Identifiers

PMID31418764
PMCPMC6927314
OpenAlexW2968091182

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.